24/7 haber gündem piyasalar sondakika
7 Gün 24 Saat Haber

Posts Tagged Novartis

Novartis hit by China, emerging market slowdown: CEO on CNBC

ZURICH (Reuters) – Drugmaker Novartis has been hit by a slowdown in emerging markets, particularly in China, where previously double-digit growth has decelerated to mid-single digits, Chief Executive Joe Jimenez said in an interview with CNBC on Friday. Reuters: Health News

Devamını Oku

Novartis to start human tests with Google lens in 2016

ZURICH (Reuters) – Novartis plans the first human tests next year of a “smart” contact lens it is developing with Google designed to help restore the eye’s natural autofocus. Reuters: Health News

Devamını Oku

Novartis buys remaining rights to GSK treatment for up to $1 billion

ZURICH (Reuters) – Novartis has agreed to buy all remaining rights to Ofatumumab from Britain’s GlaxoSmithKline for up to $ 1 billion, boosting the Swiss drugmaker’s stable of multiple sclerosis (MS) treatments. Reuters: Health News

Devamını Oku

Novartis to file for U.S. approval for two COPD treatments

ZURICH (Reuters) – Swiss pharma group Novartis said it will submit regulatory applications in the United States for two treatments against chronic obstructive pulmonary disease (COPD) after late stage clinical studies yielded good results. Reuters: Health News

Devamını Oku

Novartis copy of Amgen biotech drug shows similar efficacy-study

ZURICH (Reuters) – Novartis said its copycat version of Amgen’s Neupogen for patients with low white blood cell counts works as well as the original drug in a late-stage trial. Reuters: Health News

Devamını Oku

Novartis sees new heart failure drug as ‘multi-blockbuster’

ZURICH (Reuters) – Novartis expects its new heart failure drug to be a “multi-blockbuster” with sales between $ 2 billion and $ 5 billion, the company’s chief executive said on Tuesday. Reuters: Health News

Devamını Oku

Novartis says slimmer structure to boost profitability

ZURICH (Reuters) – Novartis AG on Wednesday shed some light on how an overhaul of its business could boost profitability even in a “brutal” era for health spending, saying the shake-up would have lifted core operating margins by 2.5 percentage points last year. Reuters: Health News

Devamını Oku

EU agency recommends against Novartis heart failure drug

ZURICH (Reuters) – EU health regulators have recommended against approving Novartis’s experimental heart failure drug for the second time this year due to insufficient evidence it improves symptoms, the Swiss drugmaker said in a statement on Friday. Reuters: Health News

Devamını Oku

Novartis lung drug not inferior to GSK’s Seretide, study shows

ZURICH (Reuters) – Patients taking Novartis’ inhaled medicine Onbrez Breezhaler for chronic lung disease had benefits similar to those taking GlaxoSmithKline’s Seretide, the Swiss drugmaker said on Friday, citing a late stage study. Reuters: Health News

Devamını Oku

Novartis psoriasis drug effective when self-administered – studies

Novartis psoriasis drug effective when self-administered – studies

ZURICH (Reuters) – Results of two late-stage clinical trials showed high efficacy for Novartis’ drug secukinumab when used by patients suffering from moderate-to-severe plaque psoriasis, the Swiss drugmaker said on Saturday. Reuters: Health News

Devamını Oku

Kitap

Teknoloji

Otomobil

Yazarlar